MedTrace Logo

Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"

NCT04213209 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 95

Last updated 2024-09-27

Study results available
· View outcomes & findings →

Summary

The purpose of this survey is to examine the safety of adult patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma (PTCL) (excluding anaplastic large cell lymphoma (ALCL)) and pediatric patients with relapsed or refractory CD30-positive PTCL or Hodgkin lymphoma (HL) in the actual use of on concomitant Brentuximab Vedotin in routine clinical practice.

Conditions

  • Peripheral T Cell Lymphoma
  • Pediatric Hodgkin Lymphoma

Interventions

DRUG

Brentuximab Vedotin (Genetical Recombination)

Brentuximab Vedotin Intravenous Infusion

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-14
Primary Completion
2023-12-13
Completion
2023-12-13

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04213209 on ClinicalTrials.gov